Jules Bordet Institute
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Private
- Established
- 1939-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.bordet.be
Clinical Trials
108
Active:20
Completed:38
Trial Phases
5 Phases
Phase 1:21
Phase 2:40
Phase 3:5
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (94 trials with phase data)• Click on a phase to view related trials
Phase 2
40 (42.6%)Not Applicable
27 (28.7%)Phase 1
21 (22.3%)Phase 3
5 (5.3%)Phase 4
1 (1.1%)Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life
Not Applicable
Not yet recruiting
- Conditions
- HypotestosteronismPalliative Care
- Interventions
- Drug: Sustanon 250
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 20
- Registration Number
- NCT07143279
Molecular Imaging of Cancer-associated Fibroblasts in Glioblastoma: a FAPI PET/MR Study.
Not Applicable
Recruiting
- Conditions
- Glioblastoma
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 50
- Registration Number
- NCT07119294
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases
Not Applicable
Recruiting
- Conditions
- Liver Metastases From Colorectal Cancer
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 50
- Registration Number
- NCT07109440
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)
Not Applicable
Not yet recruiting
- Conditions
- OligoProgressive Metastatic Disease
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 48
- Registration Number
- NCT06925984
- Locations
- 🇧🇪
Jules Bordet Institute, Brussels, Belgium
🇧🇪UZ Gent, Ghent, Belgium
🇧🇪AZ Groeninge, Kortrijk, Belgium
The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA)
Not Applicable
Recruiting
- Conditions
- Multiparametric MRILesion PI-RADS 3
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-31
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 68
- Registration Number
- NCT06867588
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
- Prev
- 1
- 2
- 3
- 4
- 5
- 19
- Next
News
No news found